Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Dopamine-glutamate interplay dysfunctions have been suggested as pathophysiological key determinants of major psychotic disorders, above all schizophrenia and mood disorders. For the most part, synaptic interactions between dopamine and glutamate signaling pathways take part in the postsynaptic density, a specialized ultrastructure localized under the membrane of glutamatergic excitatory synapses. Multiple proteins, with the role of adaptors, regulators, effectors, and scaffolds compose the postsynaptic density network. They form structural and functional crossroads where multiple signals, starting at membrane receptors, are received, elaborated, integrated, and routed to appropriate nuclear targets. Moreover, transductional pathways belonging to different receptors may be functionally interconnected through postsynaptic density molecules. Several studies have demonstrated that psychopharmacologic drugs may differentially affect the expression and function of postsynaptic genes and proteins, depending upon the peculiar receptor profile of each compound. Thus, through postsynaptic network modulation, these drugs may induce dopamine-glutamate synaptic remodeling, which is at the basis of their long-term physiologic effects. In this review, we will discuss the role of postsynaptic proteins in dopamine-glutamate signals integration, as well as the peculiar impact of different psychotropic drugs used in clinical practice on postsynaptic remodeling, thereby trying to point out the possible future molecular targets of “synapse-based” psychiatric therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
The Postsynaptic Architecture of Excitatory Synapses: A More Quantitative View
Sheng, M., & Hoogenraad, C. C. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.060805.160029 · Cited by 1,003
Leblond, C. S., Nava, C., Polge, A., Gauthier, J., Huguet, G., Lumbroso, S., Giuliano, F., Stordeur, C., Depienne, C., Mouzat, K., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004580 · Cited by 630 · cited 1×
“One possible hypothesis is that PSD molecules may concur to synaptic pathology in multiple psychiatric conditions, such as autism [47], schizophrenia [48,49], or mood disorders [50].”
BackgroundLee, F. J. S., Xue, S., Pei, L., Vukusic, B., Chéry, N., Wang, Y., Wang, Y. T., Niznik, H. B., Yu, X.-M., & Liu, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00962-5 · Cited by 542 · cited 1×
“[27], for instance, have reported direct co-immunoprecipitation of NMDA glutamate and D1 dopamine receptors in both hippocampal and striatal cultures.”
BackgroundModeling Autism by SHANK Gene Mutations in Mice
Jiang, Y.-H., & Ehlers, M. D. (2013) · Neuron · doi:10.1016/j.neuron.2013.03.016 · Cited by 488
βCaMKII in Lateral Habenula Mediates Core Symptoms of Depression
Li, K., Zhou, T., Liao, L., Yang, Z., Wong, C., Henn, F., Malinow, R., Yates, J. R., & Hu, H. (2013) · Science · doi:10.1126/science.1240729 · Cited by 411 · cited 1×
“CAMKII -Schizophrenia [172] -Major Depressive Disorder [173] -Clozapine-induced increase in prefrontal cortex activity is crucially mediated by CAMKII-NMDA receptor interactions [174] -Clozapine, haloperidol and risperidone may decrease CAMKII expression in striatum in animal models [175] -CAMKII is essential for cloz…”
BackgroundBoeckers, T. M., Bockmann, J., Kreutz, M. R., & Gundelfinger, E. D. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00931.x · Cited by 349
Genetic Risk for Schizophrenia: Convergence on Synaptic Pathways Involved in Plasticity
Hall, J., Trent, S., Thomas, K. L., O’Donovan, M. C., & Owen, M. J. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.07.011 · Cited by 290 · cited 2×
“One possible hypothesis is that PSD molecules may concur to synaptic pathology in multiple psychiatric conditions, such as autism [47], schizophrenia [48,49], or mood disorders [50].”
BackgroundLiu, R.-J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., & Aghajanian, G. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.128 · Cited by 256 · cited 6×
“NMDAR, N-methyl-D-aspartate glutamate receptor; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor; mGluR1a/5, metabotropic glutamate receptor type 1a/5; TARP, transmembrane AMPA receptors re ulatin protein or stargazin; PSD-95, postsynaptic ensity protein 95kD; DISC1, disrupted in schizoph…”
BackgroundInfluentialSynaptopathies: diseases of the synaptome
Grant, S. G. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.02.002 · Cited by 248
Cited by
Esketamine for Treatment-Resistant Depression: A Review of Clinical Evidence (Review)
Vasiliu, O. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11810 · Cited by 82
Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System
Tomasetti, C., Montemitro, C., Fiengo, A. L. C., Santone, C., Orsolini, L., Valchera, A., Carano, A., Pompili, M., Serafini, G., Perna, G., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190312102444 · Cited by 44
Self-citationFalkovich, R., Aryal, S., Sheng, M., & Bathe, M. (2024) · doi:10.1101/2024.10.28.620504 · Cited by 2
Metadata
- Authors
- Tomasetti, C., Iasevoli, F., Buonaguro, E., De Berardis, D., Fornaro, M., Fiengo, A., Martinotti, G., Orsolini, L., Valchera, A., Di Giannantonio, M., & De Bartolomeis, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-01-12
- Volume
- 18
- Issue
- 1
- Pages
- 135
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2575275441
- Cited by
- 71
- References
- 26
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.